POAI
Predictive Oncology Inc. [POAI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
POAI Stock Summary
Top 10 Correlated ETFs
POAI
Top 10 Correlated Stocks
POAI
In the News
POAI Financial details
POAI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 9.84 | 2.1 | 0.52 | 0.41 | 0.44 | |
| Net income per share | -192.02 | -63.1 | -7.16 | -9.92 | -3.48 | |
| Operating cash flow per share | -60.85 | -20.51 | -4.45 | -3.39 | -3.29 | |
| Free cash flow per share | -61.04 | -21.12 | -4.8 | -3.52 | -3.36 | |
| Cash per share | 1.05 | 1.14 | 10.28 | 6.05 | 2.17 | |
| Book value per share | 78.26 | 4.42 | 14.68 | 5.96 | 2.06 | |
| Tangible book value per share | -56.5 | -5.97 | 10.73 | 5.89 | 2 | |
| Share holders equity per share | 78.26 | 4.42 | 14.68 | 5.96 | 2.06 | |
| Interest debt per share | 38.5 | 9.83 | 0.32 | 2.97 | 0.71 | |
| Market cap | 7.49M | 8.75M | 52.24M | 22.41M | 13.21M | |
| Enterprise value | 12.87M | 13.94M | 24.92M | 519.18K | 7.34M | |
| P/E ratio | -0.27 | -0.23 | -2.66 | -0.62 | -0.94 | |
| Price to sales ratio | 5.31 | 6.99 | 36.77 | 14.89 | 7.42 | |
| POCF ratio | -0.86 | -0.71 | -4.28 | -1.81 | -1 | |
| PFCF ratio | -0.86 | -0.69 | -3.97 | -1.74 | -0.98 | |
| P/B Ratio | 0.67 | 3.31 | 1.3 | 1.03 | 1.6 | |
| PTB ratio | 0.67 | 3.31 | 1.3 | 1.03 | 1.6 | |
| EV to sales | 9.11 | 11.13 | 17.54 | 0.34 | 4.12 | |
| Enterprise value over EBITDA | -2.62 | 38.89 | -3.73 | -0.16 | -0.56 | |
| EV to operating cash flow | -1.47 | -1.14 | -2.04 | -0.04 | -0.56 | |
| EV to free cash flow | -1.47 | -1.11 | -1.89 | -0.04 | -0.54 | |
| Earnings yield | -3.68 | -4.31 | -0.38 | -1.62 | -1.06 | |
| Free cash flow yield | -1.17 | -1.44 | -0.25 | -0.57 | -1.02 | |
| Debt to equity | 0.49 | 2.22 | 0.02 | 0.01 | 0.35 | |
| Debt to assets | 0.25 | 0.45 | 0.02 | 0.01 | 0.2 | |
| Net debt to EBITDA | -1.1 | 14.49 | 4.09 | 6.62 | 0.45 | |
| Current ratio | 0.07 | 0.16 | 9.09 | 6.02 | 2.55 | |
| Interest coverage | 0 | 0 | 0 | -1.43 | 0 | |
| Income quality | 0.45 | 0.47 | 0.62 | 0.48 | 0.94 | |
| Dividend Yield | 0 | 338.7 | 0.09 | 0 | 0 | |
| Payout ratio | 0 | -78.58 | -0.23 | 0 | 0 | |
| Sales general and administrative to revenue | 6.93 | 8.27 | 7.69 | 7.38 | 5.3 | |
| Research and developement to revenue | 2.1 | 1.88 | 0.22 | 0.21 | 0.11 | |
| Intangibles to total assets | 0.86 | 0.48 | 0.25 | 0.01 | 0.02 | |
| Capex to operating cash flow | 0 | 0.03 | 0.08 | 0.04 | 0.02 | |
| Capex to revenue | -0.02 | -0.29 | -0.68 | -0.32 | -0.17 | |
| Capex to depreciation | -0.04 | -0.35 | -0.72 | -0.36 | -0.41 | |
| Stock based compensation to revenue | 1.94 | 0.94 | 4.79 | 0.35 | 0.11 | |
| Graham number | 581.49 | 79.24 | 48.64 | 36.48 | 12.71 | |
| ROIC | -1.12 | -0.1 | -0.31 | -0.97 | -1.05 | |
| Return on tangible assets | -9.08 | -5.51 | -0.6 | -1.42 | -0.99 | |
| Graham Net | -74.39 | -15.74 | 9.17 | 5.09 | 0.77 | |
| Working capital | -10.08M | -7.82M | 26.22M | 19.48M | 6.13M | |
| Tangible asset value | -8.11M | -3.57M | 29.45M | 21.51M | 8.02M | |
| Net current asset value | -10.35M | -8.9M | 25.95M | 19.39M | 3.93M | |
| Invested capital | 0.49 | 2.22 | 0.02 | 0.01 | 0.35 | |
| Average receivables | 513.47K | 276.97K | 305.54K | 342.7K | 332.45K | |
| Average payables | 1.8M | 2.26M | 1.2M | 982.61K | 1.14M | |
| Average inventory | 215.61K | 239.85K | 338.61K | 409.09K | 462.43K | |
| Days sales outstanding | 76.81 | 74.87 | 91 | 80.3 | 68.42 | |
| Days payables outstanding | 2.17K | 1.12K | 765.77 | 681.76 | 363.74 | |
| Days of inventory on hand | 130.51 | 236.32 | 290.55 | 311.08 | 133.99 | |
| Receivables turnover | 4.75 | 4.87 | 4.01 | 4.55 | 5.33 | |
| Payables turnover | 0.17 | 0.33 | 0.48 | 0.54 | 1 | |
| Inventory turnover | 2.8 | 1.54 | 1.26 | 1.17 | 2.72 | |
| ROE | -2.45 | -14.27 | -0.49 | -1.66 | -1.69 | |
| Capex per share | -0.19 | -0.6 | -0.35 | -0.13 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.09 | 0.06 | 0.12 | 0.18 | 0.08 | |
| Net income per share | -5.65 | -1.07 | -0.98 | -0.78 | -0.86 | |
| Operating cash flow per share | -0.82 | -0.86 | -0.89 | -0.77 | -0.76 | |
| Free cash flow per share | -0.84 | -0.88 | -0.96 | -0.77 | -0.76 | |
| Cash per share | 5.6 | 4.69 | 3.69 | 2.96 | 2.15 | |
| Book value per share | 5.53 | 4.68 | 3.68 | 2.89 | 2.04 | |
| Tangible book value per share | 5.46 | 4.61 | 3.61 | 2.83 | 1.97 | |
| Share holders equity per share | 5.53 | 4.68 | 3.68 | 2.89 | 2.04 | |
| Interest debt per share | -1.81 | 0.97 | 0.74 | 0.78 | 0.7 | |
| Market cap | 24.18M | 25.95M | 19.42M | 12.9M | 13.37M | |
| Enterprise value | 2.29M | 10.38M | 7.62M | 4.14M | 7.49M | |
| P/E ratio | -0.27 | -1.52 | -1.24 | -1.02 | -0.96 | |
| Price to sales ratio | 66.53 | 108.18 | 39.63 | 18.04 | 39.9 | |
| POCF ratio | -7.47 | -7.57 | -5.43 | -4.15 | -4.34 | |
| PFCF ratio | -7.33 | -7.47 | -5.07 | -4.15 | -4.35 | |
| P/B Ratio | 1.11 | 1.4 | 1.32 | 1.11 | 1.62 | |
| PTB ratio | 1.11 | 1.4 | 1.32 | 1.11 | 1.62 | |
| EV to sales | 6.3 | 43.26 | 15.56 | 5.8 | 22.37 | |
| Enterprise value over EBITDA | -4.02 | -3.22 | -2.2 | -1.38 | -2.24 | |
| EV to operating cash flow | -0.71 | -3.03 | -2.13 | -1.33 | -2.43 | |
| EV to free cash flow | -0.69 | -2.99 | -1.99 | -1.33 | -2.44 | |
| Earnings yield | -0.92 | -0.16 | -0.2 | -0.25 | -0.26 | |
| Free cash flow yield | -0.14 | -0.13 | -0.2 | -0.24 | -0.23 | |
| Debt to equity | 0.01 | 0.16 | 0.2 | 0.27 | 0.35 | |
| Debt to assets | 0.01 | 0.12 | 0.14 | 0.17 | 0.2 | |
| Net debt to EBITDA | 38.45 | 4.82 | 3.41 | 2.92 | 1.75 | |
| Current ratio | 6.02 | 5.06 | 4.24 | 3.24 | 2.55 | |
| Interest coverage | 0.6 | -4.15 | 0 | 0 | 0 | |
| Income quality | 0.41 | 1 | 0.91 | 0.98 | 0.89 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 8.38 | 9.74 | 5.52 | 3.61 | 5.39 | |
| Research and developement to revenue | 0.56 | 0.16 | 0.06 | 0.03 | 0.3 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Capex to operating cash flow | 0.02 | 0.01 | 0.07 | 0 | 0 | |
| Capex to revenue | -0.17 | -0.19 | -0.53 | -0.01 | 0.02 | |
| Capex to depreciation | -0.19 | -0.2 | -1.44 | -0.02 | 0.05 | |
| Stock based compensation to revenue | 0.31 | 0.79 | 0.01 | 0.16 | 0 | |
| Graham number | 26.51 | 10.62 | 9.02 | 7.14 | 6.26 | |
| ROIC | -0.56 | -0.18 | -0.2 | -0.18 | -0.26 | |
| Return on tangible assets | -0.87 | -0.17 | -0.19 | -0.18 | -0.25 | |
| Graham Net | 4.71 | 3.15 | 2.26 | 1.5 | 0.76 | |
| Working capital | 19.48M | 15.87M | 12.21M | 9.35M | 6.13M | |
| Tangible asset value | 21.51M | 18.28M | 14.44M | 11.39M | 8.02M | |
| Net current asset value | 19.39M | 13.27M | 9.71M | 7M | 3.93M | |
| Invested capital | 0.01 | 0.16 | 0.2 | 0.27 | 0.35 | |
| Average receivables | 327.95K | 306.98K | 356.81K | 487.8K | 439.23K | |
| Average payables | 930.36K | 1.18M | 1.22M | 1.09M | 1.26M | |
| Average inventory | 462.11K | 405.39K | 387K | 416.84K | 467.18K | |
| Days sales outstanding | 82.01 | 106.08 | 79.12 | 68.57 | 89.64 | |
| Days payables outstanding | 553.39 | 1.07K | 570.94 | 983.17 | 297.28 | |
| Days of inventory on hand | 252.51 | 284.89 | 221.79 | 370.29 | 109.51 | |
| Receivables turnover | 1.1 | 0.85 | 1.14 | 1.31 | 1 | |
| Payables turnover | 0.16 | 0.08 | 0.16 | 0.09 | 0.3 | |
| Inventory turnover | 0.36 | 0.32 | 0.41 | 0.24 | 0.82 | |
| ROE | -1.02 | -0.23 | -0.27 | -0.27 | -0.42 | |
| Capex per share | -0.02 | -0.01 | -0.06 | 0 | 0 |
POAI Frequently Asked Questions
What is Predictive Oncology Inc. stock symbol ?
Predictive Oncology Inc. is a US stock , located in Eagan of Mn and trading under the symbol POAI
What is Predictive Oncology Inc. stock quote today ?
Predictive Oncology Inc. stock price is $1.3 today.
Is Predictive Oncology Inc. stock public?
Yes, Predictive Oncology Inc. is a publicly traded company.
Company Profile
- Volume Average 24.45K
- Market Capitalization 7.15M
- Employee 34
- CEO Mr. Raymond F. Vennare
- Headquarters Eagan,MN,US
- IPO Date 2010-05-03
-
Website
https://www.predictive-oncology.com 
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
